Dyadic International IncNASDAQ:DYAI
- LAST PRICE1.8400
- TODAY'S CHANGE (%)0.1706 (10.2192%)
- Bid / Lots1.8000/ 2
- Ask / Lots1.9700/ 9
- Open / Previous Close1.6800 / 1.6694
- Day Range
- 52 Week Range
- Volume191,275
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DYAI |
|---|---|---|
| 09:32 ET | 276 | 1.68 |
| 09:48 ET | 120 | 1.6985 |
| 10:24 ET | 100 | 1.62 |
| 10:44 ET | 100 | 1.6409 |
| 10:53 ET | 2400 | 1.65 |
| 10:55 ET | 700 | 1.654 |
| 11:06 ET | 100 | 1.65 |
| 11:08 ET | 500 | 1.65 |
| 11:09 ET | 100 | 1.65 |
| 11:20 ET | 1070 | 1.58 |
| 11:31 ET | 452 | 1.5885 |
| 11:38 ET | 642 | 1.5805 |
| 11:44 ET | 480 | 1.58 |
| 12:00 ET | 1100 | 1.59 |
| 12:03 ET | 194 | 1.59 |
| 12:18 ET | 500 | 1.58 |
| 12:23 ET | 12769 | 1.64 |
| 12:25 ET | 100 | 1.64 |
| 12:27 ET | 100 | 1.64 |
| 12:30 ET | 1000 | 1.7054 |
| 12:32 ET | 2300 | 1.71 |
| 12:34 ET | 100 | 1.69 |
| 12:50 ET | 2000 | 1.6999 |
| 01:10 ET | 2099 | 1.69 |
| 01:19 ET | 967 | 1.646 |
| 01:32 ET | 1900 | 1.6454 |
| 01:33 ET | 500 | 1.6758 |
| 01:37 ET | 1057 | 1.69 |
| 01:42 ET | 1000 | 1.699 |
| 01:50 ET | 2557 | 1.6013 |
| 01:51 ET | 500 | 1.616 |
| 02:02 ET | 1000 | 1.6354 |
| 02:09 ET | 100 | 1.61 |
| 02:24 ET | 5022 | 1.64 |
| 02:29 ET | 1000 | 1.6103 |
| 02:33 ET | 2974 | 1.606 |
| 02:42 ET | 1943 | 1.66 |
| 03:21 ET | 2000 | 1.6856 |
| 03:23 ET | 4742 | 1.6819 |
| 03:25 ET | 4000 | 1.6956 |
| 03:27 ET | 11833 | 1.68 |
| 03:30 ET | 2782 | 1.7099 |
| 03:32 ET | 11198 | 1.76 |
| 03:34 ET | 2000 | 1.7844 |
| 03:36 ET | 1000 | 1.78 |
| 03:38 ET | 5598 | 1.815 |
| 03:39 ET | 8100 | 1.8 |
| 03:41 ET | 3000 | 1.85 |
| 03:43 ET | 300 | 1.7666 |
| 03:45 ET | 100 | 1.782 |
| 03:48 ET | 7231 | 1.7799 |
| 03:50 ET | 7508 | 1.8127 |
| 03:52 ET | 5640 | 1.7897 |
| 03:54 ET | 14933 | 1.8195 |
| 03:56 ET | 14820 | 1.8555 |
| 03:57 ET | 6623 | 1.8 |
| 03:59 ET | 4181 | 1.84 |
May 14, 2024
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress, from 4:00PM ET on Tuesday May 14, 2024 by Dow Jones
4:00PM ET on Tuesday May 14, 2024 by Dow JonesPress Release: Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress, from 4:00PM ET on Tuesday May 14, 2024 by Dow Jones
4:00PM ET on Tuesday May 14, 2024 by Dow Jones
May 8, 2024
Dyadic to Attend Industry and Investor Events in May, from 8:30AM ET on Wednesday May 08, 2024 by Dow Jones
8:30AM ET on Wednesday May 08, 2024 by Dow Jones
Apr 30, 2024
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024, from 4:30PM ET on Tuesday Apr 30, 2024 by Dow Jones
4:30PM ET on Tuesday Apr 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dyadic International Inc | 48.8M | -6.8x | --- |
Dare Bioscience Inc | 42.9M | -1.3x | --- |
HCW Biologics Inc | 41.8M | -1.5x | --- |
Lipocine Inc | 35.1M | -3.9x | --- |
Marker Therapeutics Inc | 36.4M | -2.9x | --- |
Clene Inc. | 47.5M | -0.8x | --- |
Company Information
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Contact Information
- Headquarters
- 1044 NORTH U.S. HIGHWAY ONE, SUITE 201JUPITER, FL, United States 33477
- Phone
- 561-743-8333
- Fax
- 561-743-8343
Executives
- Independent Chairman of the Board
- Patrick Lucy
- President, Chief Executive Officer, Director
- Mark Emalfarb
- Chief Financial Officer
- Ping Rawson
- Chief Operating Officer
- Joseph Hazelton
- Executive Vice President - Business Development
- Doug Pace
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.8M |
|---|---|
Revenue (TTM) | $2.3M |
Shares Outstanding | 29.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.83 |
EPS | $-0.27 |
Book Value | $0.20 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | 21.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -364.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
